Risultati per: Identificati potenziali bersagli per il cancro al pancreas

Pancreatic ductal adenocarcinoma (PDAC) remains the third leading cause of cancer-associated deaths in the US and is on pace to become the second leading cause of cancer-related mortality. Improvements in outcomes for those affected by pancreas cancer are primarily because of more effective systemic therapies. This includes the approval of olaparib maintenance therapy for patients with germline BRCA-variated metastatic pancreatic cancer and FOLFIRINOX or gemcitabine/capecitabine adjuvant chemotherapy regimens based off the PRODIGE24-ACCORD and ESPAC-4 trials, which demonstrated an improvement in overall survival.

Comunicato del 15/06/2022 n°31

Question: A 70-year-old Japanese woman with elevated hepatobiliary enzymes on blood test was referred to our hospital. Laboratory values were a total bilirubin of 1.8 mg/dL (reference range,